Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update
Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today reported...